Abstract
Ciprofloxacin was administered orally to 48 patients with 24 Pseudomonas aeruginosa infections and 13 other infections caused by cephalothin-resistant gram-negative bacilli. The types of infections treated included those of skin or skin structure, bone, urinary tract, and respiratory tract. In 83% of P. aeruginosa infections, a favorable clinical outcome occurred, compared with 85% for all infections. Failure to achieve a cure correlated with the emergence of resistant P. aeruginosa and Acinetobacter calcoaceticus strains in four instances and superinfection with Candida (two cases) and Streptococcus (two cases) species. Therapy was discontinued in three patients because of the development of nausea. Ciprofloxacin appears to be safe and effective in the therapy of infections caused by resistant gram-negative bacilli.
MeSH Terms
Administration, Oral
Adult
Aged
Bacterial Infections/drug therapy
Ciprofloxacin
Drug Resistance, Microbial
Female
Humans
Male
Middle Aged
Nausea/chemically induced
Pseudomonas Infections/drug therapy
Quinolines/administration & dosage,adverse effects,therapeutic use
Chemicals
Quinolines
Ciprofloxacin
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Eron L J
Harvey L
Hixon D L
Poretz D M
References (10)
10 references, click to expand
-
Tobramycin sulfate: a summary of worldwide experience from clinical trials.
J Infect Dis. 1976 Aug;134 Suppl:S219-34
PMID: 787450
-
Clinical trial of piperacillin with acquisition of resistance by Pseudomonas and clinical relapse.
Antimicrob Agents Chemother. 1980 Jul;18(1):167-70
PMID: 6448020
-
Moxalactam therapy of infections caused by cephalothin-resistant bacteria: influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapy.
Antimicrob Agents Chemother. 1981 Sep;20(3):351-5
PMID: 6458233
-
Clinical experience with Moxalactam in the treatment of pseudomonal and nonpseudomonal infections.
Antimicrob Agents Chemother. 1982 Apr;21(4):568-74
PMID: 6211137
-
A multiclinic randomized study of the comparative efficacy, safety and tolerance of imipenem/cilastatin and moxalactam.
Eur J Clin Microbiol. 1984 Oct;3(5):478-87
PMID: 6389126
-
Piperacillin therapy for Pseudomonas infections.
South Med J. 1983 Jul;76(7):859-62
PMID: 6223378
-
Ceftazidime in patients with Pseudomonas infections.
J Antimicrob Chemother. 1983 Jul;12 Suppl A:161-9
PMID: 6225762
-
Use of ceftazidime in the therapy of serious infections, including those due to multiresistant organisms.
Antimicrob Agents Chemother. 1983 Aug;24(2):176-80
PMID: 6357068
-
In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii.
Antimicrob Agents Chemother. 1984 Jul;26(1):94-6
PMID: 6236748
-
In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.
Antimicrob Agents Chemother. 1983 Apr;23(4):559-64
PMID: 6222695